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The aim of this article was to present a review of the
research literature on the outcome of botulinum toxin type A
(BTX-A) injection for management of upper limb spasticity in
children with cerebral palsy (CP). We searched the electronic
databases of MEDLINE, CINAHL and PUBMED for all
published studies with full-length English text available. For
each study, the quality of the methods and the strength of
evidence were assessed by 2 independent reviewers based on
the American Academy for Cerebral Palsy and Developmental
Medicine (AACPDM) guidelines. Four studies of level I, 8
studies of level IV and 4 studies of level V were identified.
Due to the limited number of studies with high quality
evidence and inconsistent results among studies, we were
unable to support or refute the usefulness of BTX-A injection
for management of upper limb spasticity in children with CP.
Moreover, we identified several variables that may affect the
outcome of injection, such as timing of age, dosage, dilution
volumes, localization techniques of target muscles and
participant characteristics. In summary, we have presented a
review the literature and a discussion of the considerable
uncertainty and variation associated with the clinical use of
BTX-A injection for management of upper limb spasticity in
children with CP.
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INTRODUCTION
Cerebral palsy (CP) is a non-progressive clinical
syndrome that occurs after damage to the motor
areas of the immature brain, resulting in a variety
of motor deficits.
1,2
The spastic type is the most
common form of CP. Spasticity has been con-
sidered to be a main contributor to both the
impairment of function and decreased longitudi-
nal muscle growth in the children with spastic CP,
leading to deformity.3-7 Thus, reduction of
spasticity in children with CP is important for
management of the disease. Several treatment
options have been used to reduce the spasticity
and to improve functions in children with CP.
Among them, botulinum toxin type A (BTX-A)
injection has become a popular treatment for the
spasticity in the absence of fixed deformities in the
pediatric population. Further, the use of BTX-A is
considered an effective and safe treatment for
spasticity or dystonia.8
BTX-A produces a dose-dependent, reversible
chemodenervation of the injected muscle by
blocking the presynaptic release of acetylcholine
at the neuromuscular junction.
9
There have been
many reports demonstrating that BTX-A can
reduce the spasticity/tone in lower limbs and
thereby improve locomotor ability in children
with spastic CP. In contrast, relatively few
studies are available on the use of BTX-A in the
management of upper limb spasticity in children
with CP.
There are several issues of concern associated
with improving the outcome from BTX-A injec-
tions into muscles of the upper limb: (1) selection
of target muscles, (2) localization of target
muscles, (3) optimal dose, (4) optimal timing of
age, and (5) dilution volume. In addition, a
major issue that needs attention is whether there
is sufficient evidence to support the use of
BTX-A injection into the muscles of upper limb
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in children with CP. Thus, this article presents
the results of a systematic review of the research
literature and an assessment of the issues asso-
ciated with the clinical use of BTX-A for manage-
ment of upper limb spasticity in children with
CP.
MATERIALS AND METHODS
Literature search
An extensive search of electronic databases
(MEDLINE, CINAHL and PUBMED) through
June 2006 was used to identify relevant citations
and appropriate references. The search terms
included botulinum toxin, Botox, Dysport, cere-
bral palsy, upper limb, or extremity. The
literature search was limited to published studies
where full-text was available in English. The
articles were reviewed and chosen as reference
citations if they met the following inclusion
criteria: (1) participants were children with CP
aged 0 to 19 years of age, and (2) BTX-A was
injected into the upper limb muscles for
management of spasticity. To classify the quality
of evidence and other aspects of the studies we
used the recommendations of the American
Academy for Cerebral Palsy and Developmental
Medicine (AACPDM).10 Generally speaking, level
I studies produce the most credible evidence
and, thus, yield the most definitive results. Level
II studies are based on less convincing evidence
and produce tentative conclusions. Level III and
IV reflect still less persuasive evidence and
merely suggest causation. No conclusions
regarding treatment efficacy can be drawn from
level V evidence. The quality of the studies was
rated as strong (S), moderate (M) or weak (W),
depending on the quality of the methods and
how rigorously the study design had been fol-
lowed.
Our literature search identified one double-
blinded randomized controlled trial (RCT), three
single-blinded RCTs of level I evidence, 8 pro-
spective uncontrolled studies of level IV
evidence, and 4 case studies of level V evidence
(Table 1).
RESULTS
Timing of age
It is likely that there is an optimal time during
growth and development for management of
upper limb dysfunction in children with CP.
Given this, the best responses from toxin injection
will be achieved if the toxin is injected into the
muscles of the upper limb at the optimal age. In
our literature review, the age when the children
were injected with BTX-A into the muscles of
upper limb ranged from 1 to 19 years old (Table
1). Young children below 4 years old were
injected in 7 studies.11-17 It is unknown if the
responses in these cases were better than those in
older children. Among the previous studies, only
one report addressed the effect of age on the
improvement after BTX-A injection,12 and there
was no significant relationship between age and
functional gain. On the other hand, the cases of
a previously published randomized controlled
study (RTS)11 were reanalyzed in a succeeding
report18 in order to identify a positive response
group for BTX-A injection. In the reanalysis, they
found a trend for younger children to respond
positively to the injection, but the p-value did not
reach the cutoff level for significance.
Muscle selection
The muscles selected for BTX-A injection for the
management of upper limb spasticity varied
among studies. For management of elbow flexor
spasticity, the biceps brachii was commonly
selected for injection.11,13-15,19-21 Less frequently, the
brachialis and brachioradialis were chosen to be
injected.
13,14,19
Comparisons of the outcomes
according to the muscle injected have not been
reported. For improvement of forearm supination,
the pronator teres11,13,15,19,22,23 was commonly
selected for injection and in a few cases, the pro-
nator quadratus15 was injected. Flexor carpi
ulnaris and radialis for wrist spasticity and flexor
digitorum superficialis and profundus and flexor
pollicis longus for clenched hand were chosen.
11,14,15,19,22 The flexor pollicis brevis, opponens
pollicis, adductor pollicis, and flexor pollicis
longus were also chosen to be injected for the
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management of thumb spasticity. The triceps
brachii, pectoralis muscles,19 teres major,24 and
deltoid
12
were injected in a few cases due to
shoulder deformity.
How to inject
Type of interventions before injection
The use of interventions to ease the pain and
anxiety before injection of BTX-A into the muscles
of the upper limb in children with CP varied from
general anesthesia to no intervention. A summary
of the types of interventions for BTX-A injection
from our literature review is shown in Table 2.
We found no relationship between the type of
intervention and the number of injected muscles,
the age of subjects or the method of target muscle
localization.
Table 1. Summary of Articles Reviewed
Authors Level/Quality* Study design Type of CP (No. of cases) Age (range, yrs)
Corry et al.22 I/S RCT Spastic hemiplegia (12)
Spastic quadripelgia (1)
Spastic triplegia (1)
4 - 19
Fehlings et al.18 I/S RCT Spastic hemiplegia (29) 2.5 - 10
Speth et al.23 I/S RCT Spastic hemiplegia (20) 4 - 16
Lowe et al.17 I/S RCT Spastic hemiplegia (42) 2 - 8
Wall et al.35 IV/W Case series Hemiplegia (5) Not mentioned
Denislic et al.29 IV/W Case series Dystonic (10) 7 - 15
Autti-Ramo et al.16 IV/W Case series Not mentioned (49) 2 - 16
Friedman et al.12 IV/W Case series Spastic quadriplegia (17)
Spastic hemiplegia (14)
Spastic triplegia (1)
1 - 18
Wong et al.15 IV/W Case series Spastic hemiplegia (9)
Spastic diplegia (1)
Spastic quadriplegia (1)
2 - 15
Yang et al.21 IV/W Case series Spastic diplegia (9)
Spastic hemiplegia (2)
Spastic quadriplegia (4)
4 - 13
Hurvitz et al.19 IV/W Case series Spastic hemiplegia (9) 7 - 16
Wallen et al.14 IV/M Case series Spastic (16) 1 - 14
Gooch et al.13 V/W Descriptive case report Spastic hemiplegia (1) 3
Hurvitz et al.20 V/W Descriptive case report Spastic hemiplegia (1) 16
Arens et al.28 V/W Descriptive case reports Dystonic hemiplegia (4)
Mixed hemiplegia (1)
Mixed quadriplegia (1)
12 - 19
Mall et al.24 V/W Descriptive case reports Spastic quadriplegia (2) 13 & 16
* determined by AACPDM levels of evidence classification.
10
before and after case series without control group.
CP, cerebral palsy; S, strong; M, moderate; W, weak; RCT, randomized controlled trial.
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Injection technique
There are several techniques used for needle
placement in the target muscles of the upper
limbs. The simplest method is to localize the
target muscle by anatomic knowledge and
palpation. This procedure is usually performed by
finding the largest bulk of the muscle and in-
jecting toxin into several sites at mid-belly. Other
methods that have been used to increase accuracy
include electromyographic guidance, electrical
stimulation of the target muscle, and ultrasound
guidance.
Injection techniques used in the literature are
summarized in Table 2. Six reports did not men-
tion which localization technique was used for the
needle placement. Many of the reports appeared
to use surface landmark localization for needle
placement. Three studies
12,14,23
used electrical stimu-
lation, and one study16 used electromyography
(EMG) guidance for needle placement. Both EMG
and electrical stimulation were used together in
one report.17 The dual-mode localized administra-
tion of low-dose, high-concentration BTX-A injec-
tions seemed to be an effective method for precise
needle placement. The effectiveness of sonography-
guided BTX-A injections has not been reported.
Dose and dilution volume
BTX-A toxin is known to produce a dose-
dependent chemical denervation resulting in
reduced muscular activity. However, systemic
side effects or untoward responses occur as the
total dose of BTX-A is increased. Therefore, the
BTX-A dose is a crucial determinant of outcome.
The BTX-A dosing regimens used in the published
studies varied, as seen in Table 3. The total dose
units per session, total dose units per muscle and
dose units per injection site were used to define
the dosing regimen. The injection doses for each
muscle or muscle group were calculated based on
body weight in 6 out of 16 reports (Table 3).
The total dose of toxin used per session was less
than 400 units or 12 units/kg body weight for
BOTOX (Allergan, Irvine, CA, USA) and less
than 500 units or 29 units/kg body weight for
Dysport (Porton, Speywood, UK). These values
are in accordance with the current usage guide-
lines from 1997
2
and 2000.
25
The doses per kg of
body weight used for each muscle, which were
described in 6 reports, showed a significant range
of variation: 0.5 - 3.2 units/kg/muscle for arm,
0.5 - 4.9 units/kg/muscle for forearm, and 0.9 - 1.8
units/kg/muscle for adductor pollicis.
There has been a report suggesting an optimal
dose of BTX-A for the flexor carpi radialis muscle
with the amount of reduction in the area of the
M responses.16 In this report, they suggested that
the best responses to the toxin without causing
weakness of grip strength could be achieved if the
maximal forearm doses of BOTOX were re-
stricted to 1.5 units/kg. However, the optimal
dose of the toxin for other muscles has not been
Table 2. Type of Interventions Before Injection and Localization Techniques
Type of interventions No. of studies Localization techniques (No. of studies)
General anesthesia 2 Electrical stimulation (1)
Not mentioned (1)
Topical anesthesia 4 Anatomic knowledge and palpation (3)
Electrical stimulation (1)
Oral sedation 1 Anatomic knowledge and palpation (1)
Combination of topical anesthesia and oral sedation 2 EMG-guided (1)
EMG-guided and electrical stimulation (1)
No intervention 7 Anatomic knowledge and palpation (1)
Electrical stimulation (1)
Not mentioned (5)
EMG, electromyography.
Table 3. Summary of Injection Dose in Articles Reviewed
Authors
Product
(dilution volume/dose)
Total dose Muscle (dose) Dose per site
Corry et al.22 Botox (1 mL/100 U)
Dysport (2.5 mL/500 U)
Botox 90 - 250 U
(4 - 7 U/kg)
Dysport 160 - 400 U
(8 - 9 U/kg)
- Botox (< 40U)
Dysport (< 80 U)
Fehlings et al.
18
Botox (?) 2 - 5 U/kg Biceps (1.6 - 3.2 U/kg)
Volar flexors (1.1 - 4.9 U/kg)
Pronator teres (1.1 - 1.6 U/kg)
AP (0.9 - 1.8 U/kg)
-
Speth et al.23 Botox (2 mL/100 U) < 400 U Arm (2 - 3 U/kg)
Forearm (1 - 2 U/kg)
< 50U
Lowe et al.
17
Botox (0.5mL/100 U) < 8 U/kg
(mean: 139 ± 37.48 U
range: 82 - 220 U)
Arm (3.5 U/kg)
Forearm (1.0 - 3.3 U/kg)
Hand (0.6 - 0.8 U/kg)
-
Wall et al.35 - - AP (5 ng of 0.5 cc solution) -
Denislic et al.29 Dysport (1 mL/500U) - Not mentioned (357.3 ± 99.2 U) -
Autti-Ramo et al.16 Botox (?) - AP (5 - 10U)
FPL (10 - 20 U)
Forearm (1.5 U/kg)
Arm (1 - 2 U/kg)
-
Friedman et al.12 - 6 U/kg - -
Wong et al.15
- 6 - 10 U/kg (limited at
about 100U due to
expensiveness)
Hand (25U)
Forearm (50 U)
Arm (75 - 100 U)
25U
Yang et al.21 Botox (1 mL/100 U) 100 - 200U
(mean 159 ± 43U)
Nor mentioned (1 - 2 U/kg) -
Hurvitz et al.19 Botox (2 mL/100 U) 200 - 300U Arm (50 - 100 U)
Forearm (30 - 50 U)
-
Wallen et al.
14 Botox (1 mL/100 U) < 400 U (12 U/kg) Not mentioned (0.5 - 2 U/kg/muscle) < 50U
Gooch et al.
13
- - Biceps (20 U)
BR (10U)
FCR (10 U)
-
Hurvitz et al.20 Botox (2 mL/100 U) 200 U Biceps (100U)
FCR (50 U)
FCU (50 U)
-
Arens et al.28 Botox (5 mL/100 U) 4 - 6 U/kg - -
Mall et al.24 Dysport (?) 500 U (8.3 - 29 U/kg) Teres major (500 U)
FCU (200U)
FDP (200U)
APB (100U)
GCM (500U)
-
Botox (Allergan, Irvine, CA, USA), Dysport (Porton, Speywood, UK).
AP, adductor pollicis; FPL, flexor pollicis longus; BR, brachioradialis; FCR, flexor carpi radialis; FCU, flexor carpi ulnaris; FDP, flexor
digitorum profundus; APB, abductor pollicis brevis; GCM, gastrocnemius.
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reported.
The dilution volume is a determinant for the
diffusion and spread of the toxin from the site of
injection. As BTX-A is injected into a muscle, there
is an immediate diffusion of toxin in the muscle
within a few centimeters of the needle tip.26 With
a higher volume, the areas of diffusion appear to
increase.27 The dilution volume for 100 U of
BOTOX varied from 0.5 mL
17 to 5 mL28 in the
literature. The dilution volume for Dysport was
only mentioned in one report, in which 2.5 mL of
saline was used to dilute the toxin.22 Furthermore,
a recommended dilution volume for Dysport has
yet to be found in the literature. The ideal dilution
volume for both BOTOX and Dysport injection
into muscles of the upper limbs in children with
CP has yet to be shown.
The weakening of grip strength was the only
reported untoward response to the toxin injection.
According to one report,16 impairment of grip
strength was related to an overdose of the toxin.
This report found that grip strength did not
weaken if the maximum forearm dose was limited
to 1.5 units/kg/muscle. In addition, grip strength
impairment was reported in other reports. Fehling
et al. reported a case with temporary grip strength
weakness in a single blinded RCT.11 In their study,
doses of BOTOX ranging from 1.1 to 4.9 units/
kg/muscle were injected into forearm muscles,
with doses above 1.5 units/kg/muscle injected in
10 cases (66.7%). The untoward reaction of grip
strength weakness was also noted in three cases
from the study of Wallen et al.
14
Two cases
exhibited excessive and prolonged weakness after
toxin injection into the long finger flexors. And in
the remaining case, the long finger flexors were
not injected. They reported that the weakness of
grip strength seemed to result from the spread of
toxin from the injection site of the flexor pollicis
longus to the long finger flexor. Since dosages of
BTX-A in these three cases were not mentioned in
the study, it is not known whether the untoward
reactions in these three cases were related to
overdose. Grip strength weakness after injection
was also noted in other studies, but information
about doses, target muscles and possible
explanation for the untoward reaction were not
described.
22,29
Effects of BTX-A
Effects of BTX-A on spasticity/tone and range of
motion
Spasticity or tone was measured in four RCTs
(level I), six uncontrolled studies (level IV) and
two case studies (Level V) based on different
methods and different joints (Table 4). Five
studies used the Ashworth Scale30 and seven
studies used the Modifies Ashworth Scale.31 Wrist
resonance frequency32 and Tardieu method33 were
also used as a measure of spasticity/tone. Two
RCT studies showed significantly lower values
with the Ashworth scale in the BTX-A interven-
tion group.17,22 Four uncontrolled studies also
reported a significant reduction in spasticity/tone
after intervention.12,14,15,21 The reduction of spasti-
city/tone lasted up to three months. However, the
other two RCTs and two uncontrolled studies did
not reveal any significant differences in spasti-
citiy/tone.18,19,23 Although many of the uncon-
trolled studies showed positive responses to
BTX-A, the quality of evidence in level IV studies
is too weak to support the benefits of the toxin in
spasticity/tone. However, half of the level I
studies had high quality evidence for positive
responses in spasticity/tone from BTX-A injec-
tions into the upper limb muscles.
Range of motion (ROM) was measured in three
RCTs, six uncontrolled studies and one case study
based on different methods and different joints
(Table 4). Active ROM, passive in ROM, the web-
space method and the Norkin and White pro-
cedure34 were used as a measure of ROM. Two
RCTs
22,23
showed significant improvement in
active ROM and one RCT (level I with evidence
of high quality)18 did not show any changes in
passive ROM after the toxin injection. In addition,
only two uncontrolled studies (level IV evidence
of weak quality)12,15 showed significant improve-
ment in ROM and the other four uncontrolled
studies14,16,19,35 did not show any significant
changes after the toxin injection.
Thus, the findings of the reports did not reveal
sufficient evidence to support or refute the
benefits of BTX-A injection on the spasticity/tone
and ROM of the upper limbs in children with
CP.
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Effects of BTX-A on functional gains of upper limb
The functional changes of the upper limb were
assessed in various ways. All results are displayed
in Table 5. Two RCTs, which used the Quality of
Upper Extremity Skills Test (QUEST),
36
showed
significant differences in favor of the intervention
group.17,18 Three RCTs and two uncontrolled
studies assessed Pediatric Evaluation of Disability
Inventory (PEDI), and the significant improve-
ment in the self-care domain of PEDI in one RCT18
Table 4. Effects of Botulinum Toxin Type A on Spasticity/Tone and Range of Motion in the Articles Reviewed
Authors
Spasticity/Tone Range of motion
Method Results Method Results
Corry et al.22 AS
WRF
Significant reduction at elbow (p = 0.01)
and wrist (p = 0.003) after 2 weeks,
and wrist (p = 0.01) after 12 weeks
Significant reduction after 2 weeks
(p = 0.02) and after 12 weeks (p = 0.045)
AROM Significant increase at
elbow (p = 0.026) and
thumb (p = 0.036) after
2 weeks
Fehlings et al.18 MAS Not significant PROM Not significant
Speth et al.23 AS Not significant AROM Significant increase in
supination (p = 0.006)
Lowe et al.17 AS Significant reduction (p < 0.001) Not assessed
Wall et al.35 Not assessed Web space, PROM Not significant
Denislic et al.29 AS
Decrease in tone (not statistically
analyzed)
Not assessed
Autti-Ramo et al.16 Not assessed PROM, AROM Not significant
Friedman et al.12 MAS Significant reduction (p < 0.02) ROM (Norkin
and white
Procedure)
Significant increase at
wrist (p = 0.001) and
thumb (p = 0.023)
after 1 month
Wong et al.15 MAS Significant reduction (p < 0.003) Web space,
AROM
Significant increase
(p < 0.043)
Yang et al.21 MAS Significant reduction (p < 0.05) Not assessed
Hurvitz et al.19 MAS Not significant PROM, AROM Not significant
Wallen et al.14 MAS
TS
Significant reduction at pronators
(p < 0.0001), elbow (p = 0.001) and wrist
(p = 0.001) after 2 weeks, and at wrist
(p = 0.017) after 3 months
Significant reduction at pronators (p =
0.008) and elbow (p = 0.001) after 2 weeks,
and at elbow (p = 0.001) after 3 months
PROM, AROM Not significant
Gooch et al.
13
AS Reduction Not assessed
Hurvitz et al.20 MAS Reduction PROM, AROM No difference
Arens et al.28 Not assessed Not assessed
Mall et al.24 Not assessed Not assessed
AS, Ashworth scale; MAS, modified Ashworth scale; WRF, wrist resonance frequency; AROM, active range of motion; PROM, passive
range of motion; TS, Tardieu scale.
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and one uncontrolled study,21 as well as the
functional skill of PEDI in another RCT,17 were
noted. One RCT23 and one uncontrolled study14
used the Melbourne Assessment of unilateral
upper limb function (Melbourne Assessment)37
and did not reveal any significant changes in the
scores. The existing heterogeneity among studies
in measuring the outcome of the upper spastic
limb makes it difficult to compare the results.
Three RCTs with higher quality of evidence
showed significant differences in functional ac-
tivities favoring the intervention group.17,18,22 In
the report by Fehlings et al.,18 only nine out of 14
individuals who received the toxin injection
improved. In additional analyses to determine the
predictive factors for a positive response to the
BTX-A injection, they found that adequate grip
strength before injection and younger age appear
to correlate with greater response to BTX-A.
However, one level I study did not show any
difference in functional activity between the
intervention and control groups, which had both
received rehabilitation therapy.23 And five level IV
studies with weak quality of evidence showed
some changes in function, compared with baseline
measurement.12,14,15,21,29 Another three level IV
studies failed to show significant changes in func-
tion after the toxin injection.16,19,35 Additionally,
the reported functional benefits of BTX-A varied
from simple posturing improvement to functional
improvement based on the measurements used,
with the effects for most studies lasting up to
three months after injection. Most of the other
studies did not control for factors that might affect
the outcome of the BTX-A toxin injection. The
type or intensiveness of post injection therapy
such as occupational therapy, electrical stimula-
tion and splint might also be a factor affecting the
outcome of BTX-A injections. Further, dilution
volume, dose of toxin, muscle selection method
and accurate localization of target muscles might
affect the outcome of the toxin.16 The consider-
able variation in these factors in the literature
makes it difficult to demonstrate evidence that
BTX-A injection is beneficial. Also, the patient's
characteristics such as distal voluntary control,11
grip strength,18 intact sensation, level of motiva-
tion and motor learning capacity
16
might affect the
response. The inclusion and exclusion criteria in
the literature varied widely from none to strict
regulation (Table 5). The difference in criteria for
these studies might be a factor contributing to the
wide range of toxin responses. In conclusion, the
available evidence for the short to medium term
efficacy of BTX-A injection for functional gains in
the upper limbs is promising, but not definite.
DISCUSSION
In contrast to the use of BTX-A injection into the
lower limb, the use of BTX-A injection into the
upper limb in the children with CP is currently
evolving. We only identified sixteen reports to
review for this paper. It can be said that the
ultimate goal of the clinical use of BTX-A is to get
the best results. There are several factors that may
influence the outcome of BTX-A injection: (1) op-
timal timing of age, (2) selection of target muscles,
(3) dose and dilution volume of the toxin, and (4)
ability to correctly identify the target muscle.
These factors need to be discussed before deter-
mining if there is sufficient evidence to support
the usefulness of BTX-A injection for upper limb
spasticity in children with CP.
Optimal timing of age
The timing of BTX-A injection plays a central
role for maintaining elasticity in the muscle and
reducing the development of contracture and
deformity. Some spastic muscles of the upper
limbs, such as the pronator teres and wrist flexors
may progress to muscle contracture at a faster rate
than other muscles.38 If left untreated, contracture
of these muscles may lead to bony rotational
abnormalities of the radius and ulnar. Therefore,
early use of BTX-A would be beneficial for main-
taining muscle elasticity and reducing develop-
ment of contracture and deformity.38,39 Addi-
tionally, a BTX-A injection during the period of
dynamic motor development, where there is the
greatest chance of modifying the course of the
disease, might have the potential to enhance
motor skill development.25,38 However, the results
of the studies did not show the benefits from early
use of BTX-A injection.
On the other hand, repetitive use of an affected
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muscle in daily functional tasks may reinforce the
effects of the BTX-A injection. Thus, a child's
motivation to use the affected part in daily func-
tional task seems to play a critical role in
achieving functional changes. Preschool aged
children (four to six years of age) are often very
motivated to train bimanual functions and have
good motor learning capacity.16 Therefore, four to
six years of age might seem to be an optimal age
range for getting maximal responses with the
toxin injection. This correlates with the recom-
mendation of guidelines published in 2000 by a
group of experienced BTX-A users.25 However,
since there are not sufficient numbers of reports
looking at the relationship between age of injec-
tion and response, the optimal timing for age of
BTX-A injection for management of upper limb
spasticity still remains to be answered in children
with CP.
Muscles selection
The selection of target muscles for BTX-A
injection is individualized after careful analysis of
the functional deficits, the postural deformities,
the treatment goals, and the clinician's analysis of
the muscular hypertonia and how it relates to the
individual's abilities and disabilities.18,22
The most common target muscles seen in the
literature were the biceps brachii for elbow flexor
spasticity, pronator teres for pronated forearm,
flexor carpi radialis and flexor carpi ulnaris for
wrist flexion spasticity, and adductor pollicis for
thumb in palm. In a few cases, the brachialis, or
brachioradialis, was selected for injection in an
attempt to reduce elbow flexor spasticity without
causing the loss of supinating ability. The
advantage or disadvantage of brachialis or
brachioradialis muscle injection, compared with
biceps brachii injection, has not been reported
with regard to outcome. Further study of this
issue will be helpful in selecting the target
muscle for reduction of elbow spasiticy. Apart
from the discomfort of the injection site, the only
adverse events recorded were temporary post-
injection grip strength weakness when injecting
the forearm muscles, especially long finger flexor
muscles. Therefore, it is recommended that
injection to the long finger flexor muscle or
forearm muscles should be carefully planned to
prevent the untoward reaction of grip strength
weakness.
Type of interventions before injection
Treating children before injection to ease pain
and anxiety was done with topical anesthetics,
oral sedation and general anesthesia in over 50%
of the studies. Pain and discomfort during the
procedure has prompted the use of these interven-
tions. Although the injections are generally done
quickly, they can be lengthened in the cases where
multiple muscles are injected. In addition, the
localization techniques used to improve the ac-
curacy of needle placement can evoke discomfort
and pain, which are not well tolerated in young
children. When target muscles are localized with
EMG guidance and/or electrical stimulation in a
young child or multiple muscles are injected,
pre-treating children before injection can improve
the ease of the injection procedures and decrease
anxiety during subsequent clinic visits. However,
in the literature, the type of intervention before
injection was not related to age, localization
technique or number of injected muscles.
Techniques of muscle localization
The accuracy in target muscle localization may
be a key factor determining the outcome of BTX-A
injections, more so than dilution volume and
dose. Various techniques to find the injection site
for the delivery of BTX-A into spastic skeletal
muscles have been described in the literature. The
simplest method to deliver BTX-A into muscles is
to localize the target muscle by simple palpation
and surface anatomy. It is generally accepted that
this method is suitable for large, subcutaneous
muscles. However, the accuracy of this technique
in the forearm and hand muscles is reported to be
quite low, ranging from 13% to 35%.40 Therefore,
the use of EMG or the motor point stimulation
method is recommended to identify muscles
targeted for injection, particularly for the smaller
muscles in the forearm and hand.41 The
EMG-guided method has been shown to be more
accurate in needle placement than the manual
technique. However, these methods are of limited
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use in children because the procedure is painful
and time-consuming and requires the cooperation
of the patient.41,42 Another alternative method for
improving the accuracy of needle placement is
electrical stimulation.40 Electrical stimulation is
easy to perform, does not require formal EMG
training and does not prolong the procedure
significantly. However, it is uncomfortable and
usually painful. Thus, it does require the patient
to have sedation or mask anesthesia. Although
EMG guidance and electrical stimulation have
been shown to be more accurate in needle
placement than the manual technique, their
limitations restrict the use of these techniques in
children. Half of the studies reviewed used these
techniques in needle placement. However, it
remains uncertain whether the effort to improve
the accuracy in needle placement will lead to
better responses to the toxin.
Sonography is an emerging localization tech-
nique. The visual identification of muscles and
depth control of needle placement are key
features of sonography-guided injection. The use
of sonography can prevent incorrect delivery of
BTX-A toxin. This technique is easy, quick and
painless, thus, it might be a suitable method for
use in children. There is one report on the use of
this technique for delivering BTX-A toxin into the
muscles of the upper limb in children with CP.42
This report suggested that the sonography-guided
injection technique facilitates the reliable injection
of the upper limb muscles in children with CP.
However, the outcome with sonography-guided
injection has not been reported.
One concern is whether there is a significant
relationship between target muscle localization
techniques and outcome from toxin injection.
However, the heterogeneity in the characteristics
of subjects and dosage and assessment tools
makes it difficult to compare the results of the
studies. Further research into the importance of
the method of needle localization as related to
outcome is an important area to be studied in
treating children with CP.
Dosing and dilution volume
In the search for an optimal dose of toxin for
each muscle, the ultimate goal is to achieve the
best outcome without causing the side effects of
the toxin injection. Although dosing guidelines
were established empirically by the consensus of
experienced injectors in 1997 and 2000,2,25 there is
no supporting evidence for an optimal dosage for
each muscle. Through our systemic review, we
hope to determine the optimal dose that elicits the
best response without causing untoward reac-
tions. However, in our review of the literature, the
heterogeneity in dosages used for spasticity
management of the upper limb makes it hard to
look at the dose-response relationship across the
studies.
The optimal dose of toxin was studied for the
flexor carpi radialis muscle in one report.16 For
other muscles of the upper limb, there is not
sufficient data on the optimal dose for a positive
response without side effects. Further, it is not
certain whether a higher dose produces a better
response and longer lasting effect.
An increased dilution volume can result in the
increased spread of the toxin away from the
injection site and an increased paralysis of large
muscles of the lower limb in animal studies.43,44
Increased diffusion of a higher dilution volume
could potentially spread to adjacent muscles that
are not target muscles for treatment.45 The
muscles of the upper limb in the children with CP
are smaller than the muscles of the lower limb,
and furthermore, the muscles in the hand and
forearm are adjacent to each other. So, the spread
of the toxin from the injection site could become
problematic when it comes to toxin injections in
the small muscles of the upper limb. Although 1
or 2 mL of preservative-free normal saline are
typically recommended to dilute BOTOX , 0.5 to
5 cc of normal saline have been used in the
literature. Moreover, there is a recent report of a
good response to an injection of a high con-
centration of BTX-A diluted with 0.5 cc of normal
saline. The results from this report indicated that
a better outcome might be possible through
modifying the dilution volume with considera-
tions for target muscle size and neighboring
muscles.
Impairment of grip strength was the only un-
wanted side effect when the toxin was injected
into the forearm muscle. A high toxin dose was
the suggested causative factor for the untoward
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reaction.16 However, a lack of information about
dosages used in each case made it difficult to
study the relationship between grip strength
weakness and dose. In addition, the area of
diffusion and spread of the toxin increases as the
volume increases. Therefore, it seems likely that a
high dilution volume may be a factor causing the
grip weakness. The influence of the dilution
volume on the occurrence of grip strength impair-
ment should be studied in order to improve the
outcome of BTX-A injection into the upper limb
muscles in children with CP. In addition, the
inaccuracy of target muscle localization might also
be a cause of the unwanted side effect. The
techniques used for needle placement varied in
the literature, and several studies failed to use
techniques that enhance the accuracy of needle
placement. However, it still remains uncertain
whether the accuracy of needle placement affects
the development of unwanted side effects from
BTX-A injection.
Effects of BTX-A injections
Through a systematic review of the studies
published, we tried to determine if there are
sufficient data to support the benefits of BTX-A
injection for the functional improvement in the
upper limb muscles of children with CP.
However, we found that the evidence is neither
sufficient nor consistent to support or refute the
clinical use of BTX-A injection for spastic upper
limb management in the pediatric population.
From our review, we were able to delineate the
possible reasons for the inconsistent and insuffi-
cient results from the reviewed studies.
At first, as a child grows, there is natural
improvement in CP that occurs with time and the
acquisition of functional skills. Therefore, any
changes after injection might be due to the toxin
injection, to natural improvement over time, or
both. Therefore, a good control group is vital for
the study design. However, we could only find 4
studies that had a control group, and these studies
reported various responses to the toxin. In
addition, the sample size of 106 cases in 4 level
I studies and of 137 cases in 8 level IV studies
further weakened the evidence. Second, the
assessment of the functional outcome was
quantified by methods such as QUEST and the
Melbourne upper limb assessment in only 3 level
I studies and 1 level IV study. Short-term im-
provements were found by QUEST in only 2 level
I studies and no functional gains were found by
the Melbourne assessment in one level I study
and one level IV study. The measuring tools used
in the studies varied considerably, depending, in
part, on the therapeutic aims of the injection or
other factors such as preference, availability etc.
Therefore, the inconsistent methods of measure-
ment obscure the evidence and make comparisons
between studies difficult. In addition to the
variability in assessment tools, the heterogeneity
in dosing regime, localization technique and
dilution volume make it even harder to compare
the results of the studies. Finally, selecting the
ideal candidate can affect the outcomes of BTX-A
injection. A number of authors have suggested
that children who have a favorable functional
response to BTX-A tend to be those with a
moderately high muscular tone,18,22 preserved grip
strength and younger age,18 some distal volun-
tary control,11 intact sensation and motivation to
participate in post-injection training.16 The con-
siderable heterogeneity of the participants across
the studies seemed to be one of the factors that
led to the varying responses to BTX-A injection.
We think that efforts to control these limitations
are necessary to obtain consistent evidence for the
benefit of the clinical use of BTX-A injection into
the upper limb in children with CP.
In conclusion, our systematic review of the
literature on the use of BTX-A injection for
management of upper limb spasticity in children
with CP revealed that there is not sufficient
evidence to support or refute its benefits. The
considerable variation in doses, dilution volume,
method of administration, selection of target
muscles, characteristics of subjects and assess-
ment tools make it difficult to compare the results
of the studies. In addition, the effects of the above
variables on the outcome are still unknown.
Further studies into how these variables affect the
outcome are required to help clinicians optimize
the injection strategy for BTX-A in the manage-
ment of upper limb spasticity in children with
CP.
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